NCT06177171 is a Phase 1 clinical trial of Olaparib in BRCA1 Mutation, sponsored by Pamela Munster.

Who is sponsoring NCT06177171?

NCT06177171 is sponsored by Pamela Munster.

What drugs are being tested in NCT06177171?

Interventions in NCT06177171: Olaparib, ASTX727.

What condition does NCT06177171 study?

NCT06177171 studies BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation.

Is NCT06177171 still recruiting?

NCT06177171 is currently recruiting now. Last updated 2 February 2026.

Last reviewed 2026-02-02 · How we verify

NCT06177171

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Recruiting now Phase 1 Last updated 2 February 2026

What this trial tests

Phase 1 trial testing Olaparib in BRCA1 Mutation in 18 participants. Currently enrolling.

Timeline

7 February 2024

Primary endpoint
31 January 2028

31 January 2028

Quick facts

Lead sponsor	Pamela Munster
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	7 February 2024
Primary completion	31 January 2028
Estimated completion	31 January 2028
Sites	1 location across United States

Drugs / interventions tested

Olaparib (olaparib) — full drug profile →
ASTX727 — full drug profile →

Conditions studied

BRCA1 Mutation — all drugs for BRCA1 Mutation →
BRCA2 Mutation — all drugs for BRCA2 Mutation →
BRCA Mutation — all drugs for BRCA Mutation →
PALB2 Gene Mutation — all drugs for PALB2 Gene Mutation →

Sponsor

Pamela Munster — full company profile →

Who can join

18 and older, any sex, with BRCA1 Mutation or BRCA2 Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center, phase I/Ib clinical trial evaluating the combination of the poly adenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib with the DNA methyltransferase (DNMT) inhibitor ASTX727, which is an oral formulation of decitabine with cedazuridine (a cytidine deaminase inhibitor that allows for oral administration). The study population consists of adults with advanced/metastatic solid tumor malignancies with germline or somatic mutations in the HRR pathway (i.e., BReast CAncer gene 1 (BRCA1), BReast CAncer gene 2(BRCA2), Partner And Localizer of BRCA2 (PALB2), ATM, and/or Checkpoint kinase 2 (CHEK2) mutations).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetic drugs in cancer therapy.
Suraweera A, O'Byrne KJ, Richard DJ. · · 2025 · cited 50× · PMID 40011240 · DOI 10.1007/s10555-025-10253-7
Germline Genetic Mutations in Adult Patients with Sarcoma: Insight into the Middle East Genetic Landscape.
Abu-Hijlih R, Sharaf B, Salah S, Bani Hani H, et al · · 2024 · cited 2× · PMID 38730621 · DOI 10.3390/cancers16091668
A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer.
Miller KD, Thomas A, Althouse S, Zang Y, et al · · 2026 · PMID 41980055 · DOI 10.1002/cncr.70407
DNA methyltransferase inhibitors in oncology: clinical progress, limitations and future directions.
Michael DC, Mehdipour P. · · 2026 · PMID 41762718 · DOI 10.1080/17501911.2026.2637418
Antitumor activity and structure-activity relationship of poly (ADP-ribose) polymerase (PARP)-based dual inhibitors.
Yang C, Shang Y, Li X, Li J, et al · · 2026 · PMID 41395847 · DOI 10.1080/14756366.2025.2598478

Verify or expand the search:

Other trials of Olaparib

Trials testing the same drug.

NCT05522491 — Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Br · Phase 2 · not yet recruiting
NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07407452 — Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Che · Phase 2 · not yet recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting

Other recruiting trials for BRCA1 Mutation

Currently open trials in the same condition.

NCT06972719 — Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy · NA · recruiting
NCT07253051 — BRCA Mutation Carriers' Platform a Multicenter Study · recruiting
NCT06201234 — Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+ · Phase 2 · recruiting
NCT06488378 — Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Brea · Phase 1 · recruiting
NCT05485766 — Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer · Phase 2 · recruiting

Other Pamela Munster trials

Trials by the same sponsor.

NCT05472220 — Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma · Phase 1 · withdrawn
NCT04498520 — Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer · Phase 1 · withdrawn
NCT03318445 — Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair · Phase 1 · completed
NCT02620839 — Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies · Phase 1 · terminated
NCT02358200 — Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative M · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06177171 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pamela Munster
Last refreshed: 2 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06177171.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing